Prevalence of elevated liver enzymes in children with cystic fibrosis diagnosed by newborn screen
- PMID: 27555301
- DOI: 10.1016/j.jcf.2016.08.002
Prevalence of elevated liver enzymes in children with cystic fibrosis diagnosed by newborn screen
Abstract
Background: Prevalence and risks for elevated liver enzymes have not been studied systematically in children with CF identified by newborn screen.
Methods: 298 CF children identified by newborn screen since 1982. AST, ALT and GGT tested at annual visits. Percent of children with 1 or ≥2 values of elevated AST, ALT and GGT determined. Relationship of liver enzymes to clinical factors or subsequent liver disease was analyzed RESULTS: At least one abnormal value for AST (63%), ALT (93%) and ALT ≥1.5× ULN (52%) occurred by 21years of age. Liver enzyme elevations were not correlated with CFTR mutation, meconium ileus or ethnicity. AST and GGT ≥1.5× ULN were associated with later advanced liver disease HR (CI) 6.53 (2.02-21.1) and 4.03 (1.15-13.45), respectively.
Conclusions: Elevated liver enzymes are common during childhood in CF patients identified by newborn screen. Elevated AST and GGT may be markers for risk of advanced liver disease.
Keywords: Cystic fibrosis liver disease; Newborn screening.
Copyright © 2016 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
Comment in
-
Combination CFTR modulator therapy in children and adults with cystic fibrosis.Lancet Respir Med. 2021 Jul;9(7):677-679. doi: 10.1016/S2213-2600(21)00176-4. Epub 2021 May 6. Lancet Respir Med. 2021. PMID: 33965001 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
